NF-kappa B as a target for cancer therapy (Q36709532)

15 August 2017

1 reference

title

NF-kappa B as a target for cancer therapy (English)

1 reference

15 August 2017

0 references

Davide Melisi

1

1 reference

15 August 2017

Paul J Chiao

series ordinal

2

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 February 2007

1 reference

Expert Opinion on Therapeutic Targets

15 August 2017

published in

1 reference

15 August 2017

volume

11

1 reference

15 August 2017

issue

2

1 reference

15 August 2017

page(s)

133-144

1 reference

NF-kappaB and IKK as therapeutic targets in cancer

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517/14728222.11.2.133

NF-kappaB inhibition: a double-edged sword in cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.2.133

Missing pieces in the NF-kappaB puzzle

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.2.133

NF-kappaB in cancer: from innocent bystander to major culprit

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.2.133

NF-kappaB regulation in the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.2.133

The I kappa B kinase (IKK) and NF-kappa B: key elements of proinflammatory signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.2.133

A 65-kappaD subunit of active NF-kappaB is required for inhibition of NF-kappaB by I kappaB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.2.133

Identification of an autoregulatory feedback pathway involving interleukin-1alpha in induction of constitutive NF-kappaB activation in pancreatic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.2.133

Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.2.133

IKK-gamma is an essential regulatory subunit of the IkappaB kinase complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.2.133

Regulatory functions of ubiquitination in the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.2.133

NF-kappaB at the crossroads of life and death

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.2.133

Autoregulation of I kappa B alpha activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.2.133

Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.2.133

CK2 Is a C-Terminal IκB Kinase Responsible for NF-κB Activation during the UV Response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.2.133

IkappaB kinase-independent IkappaBalpha degradation pathway: functional NF-kappaB activity and implications for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.2.133

Hydrogen peroxide activates NF-kappa B through tyrosine phosphorylation of I kappa B alpha and serine phosphorylation of p65: evidence for the involvement of I kappa B alpha kinase and Syk protein-tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.2.133

Aberrant rel/nfkb genes and activity in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.2.133

Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.2.133

Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.2.133

Rel/NF-kappa B/I kappa B signal transduction in the generation and treatment of human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.2.133

Oncogenic Ha-Ras-induced Signaling Activates NF-κB Transcriptional Activity, Which Is Required for Cellular Transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.2.133

A requirement for NF-kappa B activation in Bcr-Abl-mediated transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.2.133

Cell type-specific expression of the IkappaB kinases determines the significance of phosphatidylinositol 3-kinase/Akt signaling to NF-kappa B activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.2.133

The role of Rel/NF-κB proteins in viral oncogenesis and the regulation of viral transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.2.133

NF-kappaB and cell-cycle regulation: the cyclin connection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.2.133

Regulation of p53 tumour suppressor target gene expression by the p52 NF-kappaB subunit

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.2.133

IKKalpha controls p52/RelB at the skp2 gene promoter to regulate G1- to S-phase progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.2.133

IKK alpha regulates estrogen-induced cell cycle progression by modulating E2F1 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.2.133

Her-2/neu overexpression induces NF-kappaB via a PI3-kinase/Akt pathway involving calpain-mediated degradation of IkappaB-alpha that can be inhibited by the tumor suppressor PTEN.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.2.133

Nuclear factor-kappaB in cancer development and progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.2.133

Inhibition of constitutive NF-kappa B activity by I kappa B alpha M suppresses tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.2.133

NF-kappaB: tumor promoter or suppressor?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.2.133

p53 represses cyclin D1 transcription through down regulation of Bcl-3 and inducing increased association of the p52 NF-kappaB subunit with histone deacetylase 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.2.133

Tumor-derived p53 mutants induce oncogenesis by transactivating growth-promoting genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.2.133

IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.2.133

NF-kappaB functions as a tumour promoter in inflammation-associated cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.2.133

TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.2.133

The IKK NF-kappa B system: a treasure trove for drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.2.133

Anticancer agent CHS 828 suppresses nuclear factor-kappa B activity in cancer cells through downregulation of IKK activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.2.133

The combination of the antitumoural pyridyl cyanoguanidine CHS 828 and etoposide in vitro--from cytotoxic synergy to complete inhibition of apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.2.133

CHS 828 inhibits neuroblastoma growth in mice alone and in combination with antiangiogenic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.2.133

Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumours: an ECSG/EORTC study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.2.133

Bay 11-7082 inhibits transcription factor NF-kappaB and induces apoptosis of HTLV-I-infected T-cell lines and primary adult T-cell leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.2.133

Inhibition of NFkappaB increases the efficacy of cisplatin in in vitro and in vivo ovarian cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.2.133

Inhibition of inhibitor of nuclear factor-kappaB phosphorylation increases the efficacy of paclitaxel in in vitro and in vivo ovarian cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.2.133

Combined histone deacetylase and NF-kappaB inhibition sensitizes non-small cell lung cancer to cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.2.133

Interruption of the NF-kappaB pathway by Bay 11-7082 promotes UCN-01-mediated mitochondrial dysfunction and apoptosis in human multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.2.133

Inhibition of NF-kappaB activity by BAY 11-7082 increases apoptosis in multidrug resistant leukemic T-cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.2.133

Novel IKK inhibitors: beta-carbolines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.2.133

NF-kappa B as a therapeutic target in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.2.133

Prostate stem cell antigen is overexpressed in prostate cancer metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.2.133

The NF-kappaB pathway blockade by the IKK inhibitor PS1145 can overcome imatinib resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.2.133

BMS-345541 is a highly selective inhibitor of I kappa B kinase that binds at an allosteric site of the enzyme and blocks NF-kappa B-dependent transcription in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.2.133

BMS-345541 targets inhibitor of kappaB kinase and induces apoptosis in melanoma: involvement of nuclear factor kappaB and mitochondria pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.2.133

The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.2.133

Sulindac inhibits activation of the NF-kappaB pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.2.133

Inhibition of NF-kappa B by sodium salicylate and aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.2.133

Combination of tumor necrosis factor-alpha with sulindac augments its apoptotic potential and suppresses tumor growth of human carcinoma cells in nude mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.2.133

Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.2.133

Aminosalicylic acid inhibits IkappaB kinase alpha phosphorylation of IkappaBalpha in mouse intestinal epithelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.2.133

Inhibition of interleukin-1-stimulated NF-kappaB RelA/p65 phosphorylation by mesalamine is accompanied by decreased transcriptional activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.2.133

Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.2.133

Aspirin-like molecules that covalently inactivate cyclooxygenase-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.2.133

Does an aspirin a day keep pancreas cancer away?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.2.133

Nuclear factor kappa B activation is a potential target for preventing pancreatic carcinoma by aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.2.133

Suppression of NF-kappaB activity by sulfasalazine is mediated by direct inhibition of IkappaB kinases alpha and beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.2.133

Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.2.133

The development of proteasome inhibitors as anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.2.133

Proteasome inhibition as a novel therapeutic target in human cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.2.133

The proteasome: a suitable antineoplastic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.2.133

Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.2.133

Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.2.133

Inhibition of tumor necrosis factor-alpha -induced nuclear translocation and activation of NF-kappa B by dehydroxymethylepoxyquinomicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.2.133

Curcumin (diferuloylmethane) induces apoptosis through activation of caspase-8, BID cleavage and cytochrome c release: its suppression by ectopic expression of Bcl-2 and Bcl-xl

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.2.133

Curcumin (diferuloylmethane) inhibits constitutive NF-kappaB activation, induces G1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.2.133

Apoptosis-inducing effect of chemotherapeutic agents is potentiated by soy isoflavone genistein, a natural inhibitor of NF-kappaB in BxPC-3 pancreatic cancer cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.2.133

Flavopiridol inhibits NF-kappaB activation induced by various carcinogens and inflammatory agents through inhibition of IkappaBalpha kinase and p65 phosphorylation: abrogation of cyclin D1, cyclooxygenase-2, and matrix metalloprotease-9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.2.133

The IKK/NF-kappaB activation pathway-a target for prevention and treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.2.133

Can NF-kappaB be a target for novel and efficient anti-cancer agents?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.2.133

Inhibitors of NF-kappaB signaling: 785 and counting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.2.133

Proteasome inhibition in cancer: development of PS-341.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.2.133

Role of NF-κB in p53-mediated programmed cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728222.11.2.133

10.1517/14728222.11.2.133

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference